Implantable Cardioverter Defibrillator
13
1
1
6
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
23.1%
3 terminated out of 13 trials
66.7%
-19.8% vs benchmark
8%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Studying Routine Patient Care With BIOTRONIK Devices That Allow a More Natural Heart Stimulation
Comparison of Upper Extremity Function, Physical Activity Levels and Peripheral Muscle Strength, Fear of Movement, Balance, Activities of Daily Living and Quality of Life in Patients With Pacemakers According to Pacemaker Type
Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years
Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy
Breathing Intervention for Cardiac Anxiety
Atrial Sensing Capability for Better Detection of Atrial Fibrillation
Registry of Patients for MRI With Non-MRI Conditional Pacemakers and ICD Non-MRI Conditional Pacemakers and ICD
Clinical and Device Functional Assessment of Real World ICD Patients
Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators
Positive Therapy for Autonomic Function & Mood in ICD Patients
Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
Evaluation of an Organizational Model for Remote Monitoring of Pacemaker and Implantable Cardioverter Defibrillator Recipients
Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implantation of Defibrillators in Dilated Cardiomyopathy